These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 25318834)

  • 1. Suvorexant for the treatment of insomnia.
    Jacobson LH; Callander GE; Hoyer D
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):711-30. PubMed ID: 25318834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suvorexant: something new for sleep?
    Reddy A; Puvvada SC; Kommisetti S; El-Mallakh RS; Lippmann S
    Acta Neuropsychiatr; 2015 Feb; 27(1):53-5. PubMed ID: 25397996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
    Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
    Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
    Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
    Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suvorexant: first global approval.
    Yang LP
    Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
    Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ
    Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suvorexant: a novel therapy for the treatment of insomnia.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2014 Oct; 52(10):23-6. PubMed ID: 25291725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of suvorexant in the management of insomnia.
    Sutton EL
    Drug Des Devel Ther; 2015; 9():6035-42. PubMed ID: 26648692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.
    Vermeeren A; Vets E; Vuurman EF; Van Oers AC; Jongen S; Laethem T; Heirman I; Bautmans A; Palcza J; Li X; Troyer MD; Wrishko R; McCrea J; Sun H
    Psychopharmacology (Berl); 2016 Sep; 233(18):3341-51. PubMed ID: 27424295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
    Owen RT
    Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.
    Edmonds C; Swanoski M
    Consult Pharm; 2017 Mar; 32(3):156-160. PubMed ID: 28270270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
    Herring WJ; Roth T; Krystal AD; Michelson D
    J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-class insomnia drug on the brink of approval nod.
    Osborne R
    Nat Rev Drug Discov; 2013 Jul; 12(7):492-3. PubMed ID: 23812257
    [No Abstract]   [Full Text] [Related]  

  • 17. Suvorexant: scientifically interesting, utility uncertain.
    Keks NA; Hope J; Keogh S
    Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
    Betschart C; Hintermann S; Behnke D; Cotesta S; Fendt M; Gee CE; Jacobson LH; Laue G; Ofner S; Chaudhari V; Badiger S; Pandit C; Wagner J; Hoyer D
    J Med Chem; 2013 Oct; 56(19):7590-607. PubMed ID: 23964859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.
    Kuriyama A; Tabata H
    Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.